| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Campylobacter Infections | 11 | 2024 | 12 | 1.910 |
Why?
|
| Mycobacterium tuberculosis | 18 | 2023 | 208 | 1.720 |
Why?
|
| Campylobacter jejuni | 7 | 2021 | 15 | 1.570 |
Why?
|
| Selection, Genetic | 7 | 2020 | 537 | 1.420 |
Why?
|
| Ribonuclease H, Human Immunodeficiency Virus | 9 | 2019 | 9 | 1.200 |
Why?
|
| Models, Genetic | 7 | 2020 | 983 | 1.160 |
Why?
|
| Evolution, Molecular | 9 | 2018 | 891 | 1.100 |
Why?
|
| Siderophores | 7 | 2013 | 22 | 1.050 |
Why?
|
| Bayes Theorem | 11 | 2021 | 404 | 1.010 |
Why?
|
| Genome, Bacterial | 5 | 2024 | 159 | 0.970 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 258 | 0.920 |
Why?
|
| Ligases | 6 | 2023 | 47 | 0.880 |
Why?
|
| Pyrimidinones | 7 | 2019 | 44 | 0.840 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2016 | 395 | 0.830 |
Why?
|
| Dyslipidemias | 4 | 2015 | 109 | 0.820 |
Why?
|
| Peptide Synthases | 6 | 2016 | 12 | 0.800 |
Why?
|
| HIV Reverse Transcriptase | 6 | 2019 | 14 | 0.770 |
Why?
|
| Bacterial Proteins | 11 | 2020 | 922 | 0.770 |
Why?
|
| HIV-1 | 8 | 2019 | 182 | 0.770 |
Why?
|
| Phylogeny | 6 | 2019 | 1275 | 0.760 |
Why?
|
| Antitubercular Agents | 11 | 2020 | 62 | 0.740 |
Why?
|
| Structure-Activity Relationship | 24 | 2023 | 436 | 0.720 |
Why?
|
| Enzyme Inhibitors | 9 | 2020 | 657 | 0.710 |
Why?
|
| Gastroenteritis | 1 | 2021 | 26 | 0.710 |
Why?
|
| Reverse Transcriptase Inhibitors | 7 | 2018 | 23 | 0.700 |
Why?
|
| Silent Mutation | 1 | 2020 | 3 | 0.660 |
Why?
|
| Transaminases | 5 | 2014 | 34 | 0.660 |
Why?
|
| Genetic Techniques | 1 | 2020 | 75 | 0.640 |
Why?
|
| Biotin | 4 | 2014 | 46 | 0.640 |
Why?
|
| Staphylococcus aureus | 2 | 2013 | 287 | 0.610 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 1230 | 0.550 |
Why?
|
| Heptanoic Acids | 7 | 2014 | 72 | 0.550 |
Why?
|
| Anti-HIV Agents | 5 | 2018 | 199 | 0.540 |
Why?
|
| Pyrroles | 7 | 2014 | 172 | 0.520 |
Why?
|
| Recombination, Genetic | 5 | 2018 | 444 | 0.510 |
Why?
|
| Campylobacter | 4 | 2024 | 5 | 0.500 |
Why?
|
| Genome, Microbial | 1 | 2016 | 3 | 0.490 |
Why?
|
| Adenosine | 7 | 2020 | 278 | 0.480 |
Why?
|
| Meat | 2 | 2021 | 27 | 0.470 |
Why?
|
| Glomerular Filtration Rate | 8 | 2016 | 289 | 0.470 |
Why?
|
| Drug Design | 9 | 2019 | 133 | 0.460 |
Why?
|
| Uric Acid | 1 | 2015 | 137 | 0.460 |
Why?
|
| Biocatalysis | 3 | 2011 | 56 | 0.440 |
Why?
|
| Enzyme Assays | 2 | 2016 | 19 | 0.440 |
Why?
|
| Sirtuin 2 | 3 | 2023 | 30 | 0.420 |
Why?
|
| Tuberculosis | 4 | 2023 | 125 | 0.410 |
Why?
|
| Models, Molecular | 16 | 2018 | 1375 | 0.390 |
Why?
|
| Pyrazines | 1 | 2013 | 94 | 0.370 |
Why?
|
| Adenine | 1 | 2012 | 92 | 0.360 |
Why?
|
| Naphthyridines | 2 | 2022 | 27 | 0.360 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 39 | 0.350 |
Why?
|
| Genetic Fitness | 1 | 2011 | 45 | 0.350 |
Why?
|
| Chickens | 5 | 2024 | 212 | 0.340 |
Why?
|
| Genetics, Population | 3 | 2021 | 437 | 0.340 |
Why?
|
| Spectrophotometry | 1 | 2010 | 108 | 0.320 |
Why?
|
| Molecular Structure | 13 | 2020 | 310 | 0.320 |
Why?
|
| Antiviral Agents | 3 | 2021 | 504 | 0.320 |
Why?
|
| Animals, Wild | 2 | 2019 | 52 | 0.320 |
Why?
|
| IMP Dehydrogenase | 5 | 2010 | 9 | 0.320 |
Why?
|
| Kinetics | 9 | 2016 | 1562 | 0.320 |
Why?
|
| Microbial Sensitivity Tests | 11 | 2020 | 153 | 0.320 |
Why?
|
| Acyltransferases | 1 | 2010 | 53 | 0.310 |
Why?
|
| Hypolipidemic Agents | 1 | 2010 | 99 | 0.310 |
Why?
|
| Water Microbiology | 2 | 2009 | 16 | 0.310 |
Why?
|
| Hyperkalemia | 2 | 2021 | 18 | 0.310 |
Why?
|
| Machine Learning | 2 | 2024 | 347 | 0.310 |
Why?
|
| Coronary Disease | 4 | 2015 | 263 | 0.300 |
Why?
|
| Neisseria meningitidis | 2 | 2005 | 8 | 0.300 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 289 | 0.300 |
Why?
|
| Fluorescence Polarization | 1 | 2008 | 12 | 0.290 |
Why?
|
| Multilocus Sequence Typing | 3 | 2021 | 13 | 0.290 |
Why?
|
| Cholesterol, LDL | 5 | 2015 | 246 | 0.280 |
Why?
|
| Drosophila | 1 | 2011 | 539 | 0.260 |
Why?
|
| Humans | 50 | 2025 | 96127 | 0.260 |
Why?
|
| Drug Discovery | 3 | 2019 | 118 | 0.260 |
Why?
|
| Drosophila melanogaster | 1 | 2011 | 633 | 0.250 |
Why?
|
| Uracil | 2 | 2017 | 56 | 0.250 |
Why?
|
| Potassium | 3 | 2022 | 271 | 0.240 |
Why?
|
| Porins | 1 | 2005 | 24 | 0.240 |
Why?
|
| Coenzyme A Ligases | 2 | 2020 | 9 | 0.240 |
Why?
|
| Computer Simulation | 7 | 2018 | 1158 | 0.230 |
Why?
|
| Substrate Specificity | 5 | 2016 | 368 | 0.230 |
Why?
|
| Crystallography, X-Ray | 8 | 2017 | 527 | 0.230 |
Why?
|
| Mycophenolic Acid | 3 | 2010 | 86 | 0.220 |
Why?
|
| Workload | 1 | 2025 | 133 | 0.210 |
Why?
|
| Trauma Centers | 1 | 2025 | 174 | 0.210 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2025 | 102 | 0.210 |
Why?
|
| Cattle | 5 | 2024 | 387 | 0.210 |
Why?
|
| Sirtuin 3 | 1 | 2023 | 36 | 0.200 |
Why?
|
| Niacinamide | 3 | 2023 | 102 | 0.200 |
Why?
|
| DNA, Bacterial | 4 | 2018 | 253 | 0.200 |
Why?
|
| Animals | 19 | 2024 | 28945 | 0.190 |
Why?
|
| Coronary Artery Disease | 3 | 2016 | 394 | 0.190 |
Why?
|
| Mutation | 7 | 2012 | 4374 | 0.190 |
Why?
|
| Spironolactone | 1 | 2022 | 12 | 0.190 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2022 | 20 | 0.190 |
Why?
|
| Double-Blind Method | 7 | 2016 | 1791 | 0.190 |
Why?
|
| Anticholesteremic Agents | 3 | 2008 | 153 | 0.190 |
Why?
|
| Escherichia coli Proteins | 4 | 2013 | 190 | 0.180 |
Why?
|
| Campylobacter coli | 3 | 2010 | 4 | 0.180 |
Why?
|
| Genetic Variation | 6 | 2018 | 1423 | 0.180 |
Why?
|
| Catalytic Domain | 6 | 2019 | 165 | 0.180 |
Why?
|
| Zika Virus | 1 | 2021 | 20 | 0.170 |
Why?
|
| Zika Virus Infection | 1 | 2021 | 19 | 0.170 |
Why?
|
| Protein Structure, Tertiary | 5 | 2016 | 750 | 0.170 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 108 | 0.170 |
Why?
|
| England | 3 | 2010 | 39 | 0.170 |
Why?
|
| Surgeons | 1 | 2025 | 298 | 0.170 |
Why?
|
| Markov Chains | 2 | 2018 | 137 | 0.160 |
Why?
|
| Sulfonamides | 4 | 2020 | 338 | 0.160 |
Why?
|
| Tuberculosis, Bovine | 1 | 2019 | 1 | 0.160 |
Why?
|
| Kidney Failure, Chronic | 3 | 2009 | 432 | 0.160 |
Why?
|
| HIV Integrase Inhibitors | 2 | 2017 | 4 | 0.160 |
Why?
|
| Mycobacterium bovis | 1 | 2019 | 16 | 0.160 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 73 | 0.160 |
Why?
|
| Virus Replication | 1 | 2021 | 326 | 0.160 |
Why?
|
| HIV Infections | 6 | 2018 | 974 | 0.160 |
Why?
|
| Monte Carlo Method | 2 | 2018 | 191 | 0.160 |
Why?
|
| Time Factors | 5 | 2018 | 5585 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 2 | 2019 | 241 | 0.150 |
Why?
|
| Adenine Nucleotides | 2 | 2010 | 63 | 0.150 |
Why?
|
| Valosin Containing Protein | 1 | 2019 | 4 | 0.150 |
Why?
|
| Shigella sonnei | 1 | 2018 | 1 | 0.150 |
Why?
|
| Mycobacterium leprae | 1 | 2018 | 6 | 0.150 |
Why?
|
| Aged | 15 | 2021 | 20964 | 0.150 |
Why?
|
| Kidney | 3 | 2015 | 1156 | 0.150 |
Why?
|
| Triazoles | 2 | 2010 | 110 | 0.150 |
Why?
|
| Streptococcus pneumoniae | 1 | 2018 | 56 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2021 | 386 | 0.140 |
Why?
|
| Datasets as Topic | 1 | 2018 | 82 | 0.140 |
Why?
|
| Benchmarking | 1 | 2018 | 82 | 0.140 |
Why?
|
| Swine | 3 | 2024 | 618 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 5 | 2013 | 908 | 0.140 |
Why?
|
| Bacterial Typing Techniques | 4 | 2011 | 28 | 0.140 |
Why?
|
| Genetic Drift | 2 | 2008 | 40 | 0.130 |
Why?
|
| Hypertension | 2 | 2017 | 777 | 0.130 |
Why?
|
| Software | 2 | 2018 | 698 | 0.130 |
Why?
|
| Thiophenes | 1 | 2017 | 45 | 0.130 |
Why?
|
| HIV | 1 | 2017 | 49 | 0.130 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 157 | 0.130 |
Why?
|
| Communicable Diseases | 1 | 2018 | 69 | 0.130 |
Why?
|
| Disease Reservoirs | 3 | 2019 | 23 | 0.130 |
Why?
|
| High-Throughput Screening Assays | 3 | 2014 | 65 | 0.130 |
Why?
|
| Chelating Agents | 1 | 2017 | 68 | 0.130 |
Why?
|
| Diuretics | 1 | 2017 | 79 | 0.130 |
Why?
|
| Polymorphism, Genetic | 3 | 2011 | 829 | 0.130 |
Why?
|
| Stereoisomerism | 3 | 2011 | 104 | 0.130 |
Why?
|
| Molecular Epidemiology | 3 | 2011 | 58 | 0.130 |
Why?
|
| Ribonuclease H | 1 | 2016 | 8 | 0.130 |
Why?
|
| Lipids | 2 | 2008 | 285 | 0.130 |
Why?
|
| Cyclobutanes | 1 | 2016 | 8 | 0.120 |
Why?
|
| Molecular Docking Simulation | 4 | 2019 | 58 | 0.120 |
Why?
|
| Cluster Analysis | 3 | 2012 | 392 | 0.120 |
Why?
|
| Hydroxylamine | 1 | 2016 | 7 | 0.120 |
Why?
|
| Pravastatin | 1 | 2015 | 17 | 0.120 |
Why?
|
| Computational Biology | 2 | 2018 | 584 | 0.120 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 77 | 0.120 |
Why?
|
| Polymers | 1 | 2017 | 220 | 0.120 |
Why?
|
| Poultry | 4 | 2024 | 24 | 0.120 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2014 | 17 | 0.110 |
Why?
|
| Male | 18 | 2021 | 45870 | 0.110 |
Why?
|
| Cloning, Molecular | 2 | 2013 | 648 | 0.110 |
Why?
|
| Coenzyme A | 1 | 2014 | 13 | 0.110 |
Why?
|
| Female | 18 | 2021 | 50063 | 0.110 |
Why?
|
| Pyridines | 1 | 2016 | 319 | 0.110 |
Why?
|
| Amide Synthases | 1 | 2013 | 1 | 0.100 |
Why?
|
| Hydrazines | 1 | 2014 | 33 | 0.100 |
Why?
|
| Drug Tolerance | 1 | 2013 | 64 | 0.100 |
Why?
|
| Genomics | 1 | 2019 | 855 | 0.100 |
Why?
|
| Hydroxamic Acids | 2 | 2010 | 52 | 0.100 |
Why?
|
| Stroke | 2 | 2014 | 1087 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 1973 | 0.100 |
Why?
|
| Cell Line | 4 | 2018 | 2533 | 0.100 |
Why?
|
| Ischemic Attack, Transient | 1 | 2014 | 188 | 0.100 |
Why?
|
| Acinetobacter baumannii | 1 | 2013 | 29 | 0.100 |
Why?
|
| United States | 5 | 2025 | 7767 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 223 | 0.090 |
Why?
|
| Methicillin | 1 | 2012 | 5 | 0.090 |
Why?
|
| Cross Infection | 1 | 2013 | 159 | 0.090 |
Why?
|
| Ligands | 2 | 2014 | 478 | 0.090 |
Why?
|
| Bacteria | 1 | 2016 | 517 | 0.090 |
Why?
|
| Codon | 1 | 2011 | 120 | 0.090 |
Why?
|
| Open Reading Frames | 1 | 2011 | 124 | 0.090 |
Why?
|
| Clostridium Infections | 1 | 2013 | 128 | 0.090 |
Why?
|
| Streptavidin | 1 | 2011 | 14 | 0.090 |
Why?
|
| Binding Sites | 4 | 2017 | 1167 | 0.090 |
Why?
|
| Genome, Insect | 1 | 2011 | 78 | 0.090 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 85 | 0.090 |
Why?
|
| Fluorescence | 1 | 2011 | 106 | 0.090 |
Why?
|
| Molecular Conformation | 1 | 2011 | 111 | 0.090 |
Why?
|
| Lyases | 1 | 2010 | 11 | 0.090 |
Why?
|
| Heart Failure | 2 | 2012 | 1422 | 0.080 |
Why?
|
| Escherichia coli | 2 | 2012 | 627 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2012 | 358 | 0.080 |
Why?
|
| Nucleosides | 2 | 2008 | 23 | 0.080 |
Why?
|
| Disease Transmission, Infectious | 2 | 2013 | 60 | 0.080 |
Why?
|
| Diphosphates | 1 | 2010 | 18 | 0.080 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2010 | 20 | 0.080 |
Why?
|
| Enterobactin | 1 | 2010 | 8 | 0.080 |
Why?
|
| Pyrophosphatases | 1 | 2010 | 17 | 0.080 |
Why?
|
| Enteritis | 1 | 2010 | 23 | 0.080 |
Why?
|
| Acylation | 1 | 2010 | 68 | 0.080 |
Why?
|
| Health Surveys | 1 | 2010 | 245 | 0.080 |
Why?
|
| Chromosome Segregation | 1 | 2009 | 35 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2011 | 703 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 2794 | 0.080 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 262 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 107 | 0.080 |
Why?
|
| Vero Cells | 3 | 2020 | 106 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 7232 | 0.080 |
Why?
|
| Health Maintenance Organizations | 1 | 2009 | 20 | 0.070 |
Why?
|
| Amlodipine | 1 | 2008 | 5 | 0.070 |
Why?
|
| Compliance | 1 | 2008 | 21 | 0.070 |
Why?
|
| Hydroxybenzoates | 1 | 2008 | 6 | 0.070 |
Why?
|
| Genotype | 5 | 2011 | 1882 | 0.070 |
Why?
|
| Middle Aged | 12 | 2021 | 28363 | 0.070 |
Why?
|
| Salicylic Acid | 1 | 2008 | 39 | 0.070 |
Why?
|
| Carrier Proteins | 2 | 2013 | 684 | 0.070 |
Why?
|
| Sheep | 1 | 2008 | 250 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 901 | 0.070 |
Why?
|
| Oxazoles | 1 | 2007 | 18 | 0.070 |
Why?
|
| Arteries | 1 | 2008 | 181 | 0.070 |
Why?
|
| Rabbits | 1 | 2008 | 639 | 0.070 |
Why?
|
| Disease Progression | 1 | 2012 | 1568 | 0.070 |
Why?
|
| Genetic Speciation | 1 | 2008 | 121 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 847 | 0.070 |
Why?
|
| NAD | 2 | 2023 | 99 | 0.060 |
Why?
|
| Chemistry Techniques, Synthetic | 2 | 2017 | 9 | 0.060 |
Why?
|
| Sulfhydryl Compounds | 1 | 2007 | 72 | 0.060 |
Why?
|
| Gene Products, env | 1 | 2006 | 5 | 0.060 |
Why?
|
| Comorbidity | 1 | 2010 | 1011 | 0.060 |
Why?
|
| Birds | 1 | 2008 | 173 | 0.060 |
Why?
|
| New Zealand | 3 | 2011 | 24 | 0.060 |
Why?
|
| Prevalence | 1 | 2010 | 1349 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2009 | 594 | 0.060 |
Why?
|
| Hospitalization | 1 | 2012 | 943 | 0.060 |
Why?
|
| Biodiversity | 1 | 2008 | 238 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2017 | 111 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 2494 | 0.060 |
Why?
|
| Madin Darby Canine Kidney Cells | 2 | 2016 | 23 | 0.060 |
Why?
|
| Epidemiological Monitoring | 1 | 2024 | 43 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 3927 | 0.050 |
Why?
|
| Dogs | 2 | 2016 | 719 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 930 | 0.050 |
Why?
|
| Genes, Bacterial | 1 | 2004 | 199 | 0.050 |
Why?
|
| Poultry Diseases | 2 | 2015 | 13 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2011 | 2480 | 0.050 |
Why?
|
| Pyridones | 2 | 2016 | 68 | 0.050 |
Why?
|
| Haplotypes | 1 | 2005 | 650 | 0.050 |
Why?
|
| Incidence | 2 | 2021 | 1715 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 771 | 0.050 |
Why?
|
| NADP | 1 | 2023 | 49 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2019 | 1761 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 5960 | 0.040 |
Why?
|
| Adult | 9 | 2016 | 28718 | 0.040 |
Why?
|
| Sulfonic Acids | 2 | 2014 | 9 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 777 | 0.040 |
Why?
|
| DNA Fingerprinting | 2 | 2010 | 18 | 0.040 |
Why?
|
| Mustelidae | 1 | 2019 | 4 | 0.040 |
Why?
|
| Rural Population | 2 | 2011 | 171 | 0.040 |
Why?
|
| Food Microbiology | 2 | 2009 | 11 | 0.040 |
Why?
|
| Urban Population | 2 | 2011 | 240 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 2422 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2019 | 65 | 0.040 |
Why?
|
| Sierra Leone | 1 | 2018 | 3 | 0.040 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2018 | 12 | 0.040 |
Why?
|
| Methylation | 1 | 2018 | 295 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2017 | 24 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2017 | 43 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 98 | 0.030 |
Why?
|
| Risk | 2 | 2008 | 668 | 0.030 |
Why?
|
| Raltegravir Potassium | 1 | 2016 | 2 | 0.030 |
Why?
|
| HIV Integrase | 1 | 2016 | 5 | 0.030 |
Why?
|
| Oxazines | 1 | 2016 | 15 | 0.030 |
Why?
|
| Constipation | 1 | 2017 | 69 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 48 | 0.030 |
Why?
|
| Crystallization | 1 | 2017 | 216 | 0.030 |
Why?
|
| Drug Stability | 1 | 2016 | 50 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2016 | 49 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2016 | 44 | 0.030 |
Why?
|
| alpha-Synuclein | 1 | 2016 | 24 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2011 | 983 | 0.030 |
Why?
|
| Cattle Diseases | 1 | 2015 | 7 | 0.030 |
Why?
|
| Guanosine | 1 | 2016 | 31 | 0.030 |
Why?
|
| Swine Diseases | 1 | 2015 | 15 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 119 | 0.030 |
Why?
|
| Host Specificity | 1 | 2015 | 13 | 0.030 |
Why?
|
| Mice | 3 | 2016 | 12562 | 0.030 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2016 | 106 | 0.030 |
Why?
|
| Calorimetry | 1 | 2014 | 16 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2024 | 10286 | 0.030 |
Why?
|
| Creatinine | 1 | 2016 | 299 | 0.030 |
Why?
|
| Sirtuins | 1 | 2016 | 80 | 0.030 |
Why?
|
| Suramin | 1 | 2014 | 25 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 278 | 0.030 |
Why?
|
| Neoplasms | 1 | 2010 | 3250 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2014 | 154 | 0.030 |
Why?
|
| Piperazines | 1 | 2016 | 296 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 120 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2016 | 4671 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 130 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2013 | 120 | 0.020 |
Why?
|
| Child | 3 | 2010 | 7626 | 0.020 |
Why?
|
| United Kingdom | 1 | 2013 | 192 | 0.020 |
Why?
|
| Amino Acids | 1 | 2014 | 262 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2010 | 3974 | 0.020 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 308 | 0.020 |
Why?
|
| Hydrolases | 1 | 2012 | 31 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2010 | 2614 | 0.020 |
Why?
|
| Models, Biological | 2 | 2011 | 1815 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2011 | 23 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 1986 | 0.020 |
Why?
|
| Adolescent | 3 | 2010 | 9896 | 0.020 |
Why?
|
| Scotland | 1 | 2010 | 5 | 0.020 |
Why?
|
| Sulfones | 1 | 2010 | 46 | 0.020 |
Why?
|
| Calibration | 1 | 2010 | 108 | 0.020 |
Why?
|
| Agriculture | 1 | 2010 | 44 | 0.020 |
Why?
|
| Cinnamates | 1 | 2010 | 8 | 0.020 |
Why?
|
| Pantothenic Acid | 1 | 2010 | 1 | 0.020 |
Why?
|
| Ruminants | 1 | 2010 | 6 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2010 | 63 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 564 | 0.020 |
Why?
|
| Foodborne Diseases | 1 | 2010 | 9 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 130 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 935 | 0.020 |
Why?
|
| Dimerization | 1 | 2010 | 150 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2010 | 112 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 198 | 0.020 |
Why?
|
| Poultry Products | 1 | 2009 | 2 | 0.020 |
Why?
|
| Catalysis | 1 | 2010 | 216 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2009 | 54 | 0.020 |
Why?
|
| Crossing Over, Genetic | 1 | 2009 | 34 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 86 | 0.020 |
Why?
|
| Manure | 1 | 2009 | 5 | 0.020 |
Why?
|
| Zoonoses | 1 | 2009 | 28 | 0.020 |
Why?
|
| Animals, Domestic | 1 | 2009 | 12 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 84 | 0.020 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2008 | 7 | 0.020 |
Why?
|
| Seasons | 1 | 2010 | 246 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 213 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2009 | 218 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1034 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2008 | 187 | 0.020 |
Why?
|
| Triglycerides | 1 | 2008 | 236 | 0.020 |
Why?
|
| Young Adult | 2 | 2010 | 7025 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 325 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 1157 | 0.020 |
Why?
|
| Feces | 1 | 2009 | 360 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2007 | 82 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2007 | 173 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 813 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2006 | 109 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 647 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 910 | 0.020 |
Why?
|
| HIV Core Protein p24 | 1 | 2006 | 6 | 0.020 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2006 | 16 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2006 | 79 | 0.020 |
Why?
|
| Homosexuality | 1 | 2006 | 10 | 0.020 |
Why?
|
| Cell Wall | 1 | 2006 | 75 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2006 | 45 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 329 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 1763 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2009 | 9173 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2007 | 325 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2551 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 929 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 3363 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2009 | 1276 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 2344 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 3041 | 0.010 |
Why?
|